Tim Wright, Editor, Contract Pharma02.12.21
Pfizer and BioNTech SE said that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.
“We support the new administration's plan to vaccinate as many people as quickly as possible because there is an urgent need to help protect people from this virus, here in the U.S. and across the globe,” said Albert Bourla, chairman and chief executive officer, Pfizer. "We are pleased to work with the administration to provide these additional vaccines, so that more Americans receive their first and second doses as soon as possible."
Ugur Sahin, chief executive officer, BioNTech, said, “It is our objective to supply as many doses of our COVID-19 vaccine as possible to people in order to help end this pandemic, reduce the hospitalization of especially elderly people and bring us back to our normal lives.”
Consistent with the agreements for the prior 200 million doses, the U.S. government will pay $1.95 billion for the additional 100 million doses. Eligible U.S. residents will continue to receive the vaccine for free, consistent with the U.S. government’s commitment for free access for COVID-19 vaccines.
Pfizer’s facility in Kalamazoo, MI, remains the primary manufacturing site of the Pfizer-BioNTech COVID-19 vaccine in the U.S.
“We support the new administration's plan to vaccinate as many people as quickly as possible because there is an urgent need to help protect people from this virus, here in the U.S. and across the globe,” said Albert Bourla, chairman and chief executive officer, Pfizer. "We are pleased to work with the administration to provide these additional vaccines, so that more Americans receive their first and second doses as soon as possible."
Ugur Sahin, chief executive officer, BioNTech, said, “It is our objective to supply as many doses of our COVID-19 vaccine as possible to people in order to help end this pandemic, reduce the hospitalization of especially elderly people and bring us back to our normal lives.”
Consistent with the agreements for the prior 200 million doses, the U.S. government will pay $1.95 billion for the additional 100 million doses. Eligible U.S. residents will continue to receive the vaccine for free, consistent with the U.S. government’s commitment for free access for COVID-19 vaccines.
Pfizer’s facility in Kalamazoo, MI, remains the primary manufacturing site of the Pfizer-BioNTech COVID-19 vaccine in the U.S.
